Biotron Limited (BIT.AX)
Biotron Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Sydney, NSW, AU. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3.3M. Its beta of -0.61 implies it has historically moved less than the broad market.
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
Biotron Limited is most often compared with the following Healthcare names: